Tesamorelin
Dosage Protocol
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) with an added trans-3-hexenoic acid group that stabilises the molecule against plasma degradation. It stimulates the pituitary to secrete endogenous growth hormone in a pulsatile, physiological manner — making it distinct from direct GH administration.
What is Tesamorelin?
Unlike direct growth hormone peptides (GHRPs) or exogenous GH, tesamorelin works upstream at the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile endogenous GH secretion. This preserves physiological feedback mechanisms, reducing the risk of GH-related adverse effects associated with supraphysiological GH exposure.
Tesamorelin (Egrifta) has FDA approval for HIV-associated lipodystrophy — visceral fat accumulation in HIV-positive patients on antiretroviral therapy. Research interest extends to metabolic health, body composition, cognitive function (particularly in early Alzheimer's research), and age-related GH decline.
Dosing Schedule
Parameters documented in published preclinical and clinical research.
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Standard typical | 1 mg | Once daily (evening) | 3–6 months | Most common research protocol. Evening dosing aligns with natural GH pulse timing. |
| Higher dose | 2 mg | Once daily | 3–6 months | Used in some body composition research protocols. |
| Off cycle | — | — | 1–2 months | Rest period between extended research cycles. |